Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.

Blum K, Han D, Baron D, Kazmi S, Elman I, Gomez LL, Gondre-Lewis MC, Thanos PK, Braverman ER, Badgaiyan RD

Current psychiatry research and reviews21 Jun 2022Cited by 3 (Europe PMC)

PMID36118157PMCIDPMC9474872DOI10.2174/2666082218666220527114427PepBankPUB-36118157

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

01HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In treatment-resistant substance use disorder, IV1114589NAD reduced craving scores from baseline.
In plain wordsIn treatment-resistant substance use disorder, the NAD+ combination infusion reduced craving scores from baseline.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
DecreaseCraving score
Study
n = 50
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Source sentences
Summary
Using Wilcoxon signed-rank tests and sign tests, our team detected significant results by comparing baseline to post outcome scores after IV1114589NAD injections: craving scores (P=1.063E-9); anxiety (P=5.487E-7); and depression (P=1.763E-4).
4 context sentences(design, population, supporting numbers)
Summary · context
A significant reduction in cravings, anxiety, and depression followed a dose-dependent linear trend.
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
Title · context
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815701
02HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In treatment-resistant substance use disorder, IV1114589NAD reduced anxiety scores from baseline.
In plain wordsIn treatment-resistant substance use disorder, the NAD+ combination infusion reduced anxiety scores from baseline.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
DecreaseAnxiety score
Study
n = 50
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
Using Wilcoxon signed-rank tests and sign tests, our team detected significant results by comparing baseline to post outcome scores after IV1114589NAD injections: craving scores (P=1.063E-9); anxiety (P=5.487E-7); and depression (P=1.763E-4).
4 context sentences(design, population, supporting numbers)
Summary · context
A significant reduction in cravings, anxiety, and depression followed a dose-dependent linear trend.
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
Title · context
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815702
03HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In treatment-resistant substance use disorder, IV1114589NAD reduced depression scores from baseline.
In plain wordsIn treatment-resistant substance use disorder, the NAD+ combination infusion reduced depression scores from baseline.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
DecreaseDepression score
Study
n = 50
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
Using Wilcoxon signed-rank tests and sign tests, our team detected significant results by comparing baseline to post outcome scores after IV1114589NAD injections: craving scores (P=1.063E-9); anxiety (P=5.487E-7); and depression (P=1.763E-4).
4 context sentences(design, population, supporting numbers)
Summary · context
A significant reduction in cravings, anxiety, and depression followed a dose-dependent linear trend.
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
Title · context
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815703
04HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In substance use disorder, NAD+ combination infusions showed a significant dose-dependent linear decrease in craving scores.
In plain wordsIn substance use disorder, craving scores decreased with the dose of NAD+ combination infusions.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
DecreaseDose-dependent craving score trend
Study
n = 50
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Measurements
P value for dose-dependent craving score linear trend
0.015 p value
relationship between NAD infusions and decreasing craving scores
Source sentences
Summary
Linear trend analyses showed a significant relationship between NAD infusions and decreasing scores for cravings (P=0.015), anxiety (P=0.003), and depression (P=8.74E-5).
4 context sentences(design, population, supporting numbers)
Summary · context
A significant reduction in cravings, anxiety, and depression followed a dose-dependent linear trend.
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
Title · context
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815704
05HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In substance use disorder, NAD+ combination infusions showed a significant dose-dependent linear decrease in anxiety scores.
In plain wordsIn substance use disorder, anxiety scores decreased with the dose of NAD+ combination infusions.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
DecreaseDose-dependent anxiety score trend
Study
n = 50
Outcome group
Anxiety and mood · Mental health and mood
Measurements
P value for dose-dependent anxiety score linear trend
0.003 p value
relationship between NAD infusions and decreasing anxiety scores
Source sentences
Summary
Linear trend analyses showed a significant relationship between NAD infusions and decreasing scores for cravings (P=0.015), anxiety (P=0.003), and depression (P=8.74E-5).
4 context sentences(design, population, supporting numbers)
Summary · context
A significant reduction in cravings, anxiety, and depression followed a dose-dependent linear trend.
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
Title · context
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815705
06HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In substance use disorder, NAD+ combination infusions showed a significant dose-dependent linear decrease in depression scores.
In plain wordsIn substance use disorder, depression scores decreased with the dose of NAD+ combination infusions.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
DecreaseDose-dependent depression score trend
Study
n = 50
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
Linear trend analyses showed a significant relationship between NAD infusions and decreasing scores for cravings (P=0.015), anxiety (P=0.003), and depression (P=8.74E-5).
4 context sentences(design, population, supporting numbers)
Summary · context
A significant reduction in cravings, anxiety, and depression followed a dose-dependent linear trend.
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
Title · context
Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815706
07HumanNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneCase report or seriesEfficacy outcome
In a subset receiving NAD+ combination infusions, all analyzed urine samples lacked detectable illicit substance use midway through the study.
In plain wordsIn patients receiving NAD+ combination infusions, all analyzed urine samples lacked detectable illicit substances midway through the study.
Peptide
NAD+ (nicotinamide adenine dinucleotide)
Outcome
Not applicableUrine illicit substance detection
Study
n = 40
Outcome group
Patterns of use · Mental health and mood
Measurements
Urine samples without detected illicit substance use
100%
subset of 40 patients
Source sentences
Summary
A urine analysis was conducted on a subset of 40 patients midway through the study to assess relapse; 100% of the urine samples analyzed failed to detect illicit substance use.
2 context sentences(design, population, supporting numbers)
Summary · context
The study cohort consisted of addicted poly-drug, mixed gender, multi-ethnic individuals resistant to standard treatment.
Summary · context
The investigation utilized Likert-Scales to assess behavioral outcomes.
In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).
Report a problemFND-3611815707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.